Mercer Global Advisors
RVMD icon

Mercer Global Advisors’s Revolution Medicines RVMD Stock Holding History

Mercer Global Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8K Buy
+1,000
New +$146K ﹤0.01% 4299

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mercer Global Advisors's RVMD Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Revolution Medicines (RVMD) in Q2 2026: 17,432 shares worth $3.26M. The stake represents ﹤0.01% of the portfolio and ranks #1073 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in RVMD as recently as Q3 2025.

Mercer Global Advisors first reported a position in RVMD in Q3 2025 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Mercer Global Advisors held 17,432 shares of Revolution Medicines worth $3.26M as of Q2 2026.
  • Revolution Medicines was a new Mercer Global Advisors position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1073 holding.
  • Mercer Global Advisors first reported a position in Revolution Medicines in Q3 2025 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.